Novan, Inc. (NOVN): Price and Financial Metrics

Novan, Inc. (NOVN): $2.79

-0.13 (-4.45%)

POWR Rating

Component Grades














  • NOVN scores best on the Sentiment dimension, with a Sentiment rank ahead of 63.17% of US stocks.
  • The strongest trend for NOVN is in Stability, which has been heading up over the past 179 days.
  • NOVN's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

NOVN Stock Summary

  • With a year-over-year growth in debt of 277.93%, Novan Inc's debt growth rate surpasses 95.68% of about US stocks.
  • As for revenue growth, note that NOVN's revenue has grown -39.88% over the past 12 months; that beats the revenue growth of only 4.25% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NOVN comes in at -65.27% -- higher than that of only 6.43% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novan Inc are NVEC, GBS, PALT, IMOS, and MNDO.
  • Visit NOVN's SEC page to see the company's official filings. To visit the company's web site, go to

NOVN Valuation Summary

  • NOVN's price/sales ratio is 45.6; this is 1100% higher than that of the median Healthcare stock.
  • NOVN's EV/EBIT ratio has moved up 1.6 over the prior 60 months.
  • NOVN's price/earnings ratio has moved down 0.2 over the prior 60 months.

Below are key valuation metrics over time for NOVN.

Stock Date P/S P/B P/E EV/EBIT
NOVN 2021-08-31 45.6 5.6 -6.0 -3.9
NOVN 2021-08-30 45.4 5.6 -6.0 -3.9
NOVN 2021-08-27 45.6 5.6 -6.0 -3.9
NOVN 2021-08-26 43.9 5.4 -5.8 -3.7
NOVN 2021-08-25 44.9 5.5 -5.9 -3.8
NOVN 2021-08-24 45.9 5.6 -6.0 -3.9

NOVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NOVN has a Quality Grade of D, ranking ahead of 5.71% of graded US stocks.
  • NOVN's asset turnover comes in at 0.072 -- ranking 285th of 682 Pharmaceutical Products stocks.
  • VBIV, RIOT, and ASRT are the stocks whose asset turnover ratios are most correlated with NOVN.

The table below shows NOVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.072 1 -8.838
2021-03-31 0.097 1 -7.579
2020-12-31 0.111 1 -7.267
2020-09-30 0.132 1 -3.706
2020-06-30 0.140 1 -2.821
2020-03-31 0.134 1 -5.195

NOVN Price Target

For more insight on analysts targets of NOVN, see our NOVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.00 Average Broker Recommendation 1.5 (Moderate Buy)

NOVN Stock Price Chart Interactive Chart >

Price chart for NOVN

NOVN Price/Volume Stats

Current price $2.79 52-week high $20.74
Prev. close $2.92 52-week low $2.24
Day low $2.66 Volume 111,000
Day high $2.94 Avg. volume 145,194
50-day MA $3.13 Dividend yield N/A
200-day MA $5.30 Market Cap 53.49M

Novan, Inc. (NOVN) Company Bio

Novan, Inc. focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company was founded in 2006 and is based in Durham, North Carolina.

NOVN Latest News Stream

Event/Time News Detail
Loading, please wait...

NOVN Latest Social Stream

Loading social stream, please wait...

View Full NOVN Social Stream

Latest NOVN News From Around the Web

Below are the latest news stories about Novan Inc that investors may wish to consider to help them evaluate NOVN as an investment opportunity.

Novan GAAP EPS of -$1.74, revenue of $2.96M

Novan press release (NASDAQ:NOVN): Q4 GAAP EPS of -$1.74. Revenue of $2.96M (-39.8% Y/Y). The Company reported a cash and cash equivalents balance of $47.1 million as of December 31, 2021....

Seeking Alpha | February 22, 2022

Novan, Inc. (NOVN) CEO Paula Brown Stafford On Q4 2021 Results - Earnings Call Transcript

Novan, Inc. (NOVN) Q4 Earnings Conference Call February 22, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman and Chief Executive Officer John M. Gay - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Capital Jennifer Kim - Cantor Fitzgerald Oren Livnat - HC Wainwright John...

SA Transcripts on Seeking Alpha | February 22, 2022

Novan Reports Full Year 2021 Financial Results and Provides Corporate Update

– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline assets SB019, for the treatment of SARS-CoV-2, toward a Phase 1 study in 2022, and SB204, for the treatment of acne vulgaris, toward a registrational Phase 3 study in 2023 – – Company to host update conference call and webcast today at 8:30 a.m. ET – DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Novan,

Yahoo | February 22, 2022

Novan to Report Full Year 2021 Financial Results on February 22, 2022

DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan m

Yahoo | February 15, 2022

TBJ reveals 2022 Women in Business Lifetime Achievement Award winner

A longtime life sciences industry executive has been named Triangle Business Journal’s 2022 Women in Business Lifetime Achievement Award winner.

Yahoo | February 10, 2022

Read More 'NOVN' Stories Here

NOVN Price Returns

1-mo -6.38%
3-mo -29.01%
6-mo -47.26%
1-year -78.54%
3-year -87.92%
5-year -94.46%
YTD -33.09%
2021 -48.71%
2020 -74.27%
2019 280.72%
2018 -80.33%
2017 -84.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7253 seconds.